PRIA Logo™
117-hr-7828117th Congress

PRICED Act

Sponsored By: Representative Schakowsky, Janice D. [D-IL-9]

Unknown

Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Schakowsky, Janice D. [D-IL-9]

IL • D

Cosponsors

  • Rep. Westerman, Bruce [R-AR-4]

    AR • R

    Sponsored 5/18/2022

  • Rep. Khanna, Ro [D-CA-17]

    CA • D

    Sponsored 5/18/2022

  • Rep. Doggett, Lloyd [D-TX-37]

    TX • D

    Sponsored 5/18/2022

  • Rep. Pocan, Mark [D-WI-2]

    WI • D

    Sponsored 5/18/2022

  • Rep. Kaptur, Marcy [D-OH-9]

    OH • D

    Sponsored 5/18/2022

  • Rep. García, Jesús G. "Chuy" [D-IL-4]

    IL • D

    Sponsored 5/18/2022

  • Rep. DeLauro, Rosa L. [D-CT-3]

    CT • D

    Sponsored 5/18/2022

  • Rep. Krishnamoorthi, Raja [D-IL-8]

    IL • D

    Sponsored 5/24/2022

  • Rep. Levin, Andy [D-MI-9]

    MI • D

    Sponsored 7/12/2022

  • Rep. Jayapal, Pramila [D-WA-7]

    WA • D

    Sponsored 7/12/2022

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation